Abbot Laboratories


William Blair Reaffirms Outperform On Abbot Following The Sale Of Generic Drugs Business

In a research note issued yesterday, William Blair analyst Ben Andrew reaffirmed an Outperform rating on Abbott Laboratories (ABT). The report followsyesterday’s news that Abbott will …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts